Nanotechnology Now







Heifer International

Wikipedia Affiliate Button


DHgate

Home > Press > Ferrari & siRNA featured in Houston Chronicle

Abstract:
Arrowhead Lead Scientific Advisor, Dr. Mauro Ferrari and Calando Pharmaceuticals' siRNA drug delivery platform featured in Houston Chronicle

Ferrari & siRNA featured in Houston Chronicle

Pasadena, CA | Posted on May 28th, 2010

Arrowhead Research Corporation (NASDAQ: ARWR) today announced that two articles of interest to Arrowhead stockholders appeared in the Houston Chronicle this week. An article published on May 24, entitled "Minute invaders that aid the body", reports on the revolutionary potential of gene silencing and the pioneering role of the siRNA delivery system developed by Arrowhead majority-owned subsidiary, Calando Pharmaceuticals and Caltech engineering professor, Dr. Mark Davis. The article described preliminary data from Calando's Phase I clinical trial, recently published in the journal Nature, that demonstrated effective siRNA delivery to tumor cells and gene silencing via RNAi for the first time in humans. Dr. Davis discussed the results, and Dr. Mauro Ferrari, Chairman of NanoMedicine and Biomedical Engineering at the University of Texas Medical School, is quoted in the article about the work and the power of RNA interference: "These are very sophisticated ways of sending biological messages to the body. It will change medicine completely."

The May 24 article can be here: www.chron.com/disp/story.mpl/metropolitan/7019056.html

Dr. Ferrari was also interviewed for a May 23 article, entitled "A big mission for a big business." The article focused on the growing importance of nanomedicine for the Houston economy. Dr. Ferrari has brought in close to $70 million in grants for nanomedicine research, much of which funds work done in partnership with Arrowhead portfolio company, Leonardo Biosystems. Located in Houston, Leonardo was co-founded by Dr. Ferrari and Arrowhead's CEO, Christopher Anzalone to commercialize a next generation drug delivery platform known as multistage vectors (MSV) for treating cancer. Dr. Ferrari also heads a consortium of eight research hospitals and universities known as the Alliance for Nanohealth, and this concentration of well-funded world-class research is thought to be a significant economic driver for the Houston area going forward.

"We have assembled some of the world's great scientists and established a system for them to work together, often across disciplines, to attack fundamental challenges in medicine," said Dr. Ferrari. "We are also working closely with industry and the state of Texas to convert these advances into new therapies." As an example, in the current issue of Cancer Research, Dr. Ferrari and collaborators report delivering siRNA in mouse ovarian cancer models with MSV to provide therapeutic efficacy for three weeks or more after a single injection. Leonardo is commercializing this technology, and there are ongoing interactions between academic labs and the company. Dr. Ferrari continued, "The time-extended release of siRNA from systemic injections, coupled with the ability to overcome the body's physiological barriers to delivery are next major frontiers of siRNA delivery. The MSV system provides an ideal means of delivery for these functions, and the academic-industry collaborations involved here represent a good model for Houston and beyond."

The May 23 article: www.chron.com/disp/story.mpl/business/chron10010/7017488.html

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties. For example, there can be no assurance that Calando's or Leonardo's technology will be successfully developed or that early-stage clinical results will be replicated in larger subsequent trials. Arrowhead Research Corporation's Annual Report on Form 10-K and 10-K/A, recent and forthcoming Quarterly Reports on Form 10-Q and 10-Q/A, recent Current Reports on Forms 8-K and 8-K/A, our Registration Statements on Form S-1, and other SEC filings discuss these and other important risk factors that may affect our business, results of operations and financial condition. We disclaim any intent to revise or update publicly any forward-looking statements.

####

About Arrowhead Research Corporation
Arrowhead Research Corporation (www.arrowheadresearch.com) (NASDAQ: ARWR) is a nanotechnology company commercializing new technologies in the areas of life sciences and electronics. Arrowhead is seeking to build value for shareholders through the progress of its portfolio companies. Currently, Arrowhead is focused primarily on its two majority owned subsidiaries, Unidym, a leader in carbon nanotube technology for electronic applications, and Calando, at the forefront of clinical application of RNAi delivery technology. Arrowhead also has minority investments in two privately held nanobiotech companies, including Nanotope, Inc.

For more information, please click here

Contacts:
Brandi Floberg
The Piacente Group
212-481-2050

Copyright © Arrowhead Research Corporation

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Graphene Shows Promise In Eradication Of Stem Cancer Cells March 1st, 2015

Novel Method to Determine Optical Purity of Drug Components March 1st, 2015

Scientific breakthrough in rechargeable batteries: Researchers from Singapore and Québec Team Up to Develop Next-Generation Materials to Power Electronic Devices and Electric Vehicles February 28th, 2015

First detailed microscopy evidence of bacteria at the lower size limit of life: Berkeley Lab research provides comprehensive description of ultra-small bacteria February 28th, 2015

Nanomedicine

Graphene Shows Promise In Eradication Of Stem Cancer Cells March 1st, 2015

Novel Method to Determine Optical Purity of Drug Components March 1st, 2015

Untangling DNA with a droplet of water, a pipet and a polymer: With the 'rolling droplet technique,' a DNA-injected water droplet rolls like a ball over a platelet, sticking the DNA to the plate surface February 27th, 2015

Graphene shows potential as novel anti-cancer therapeutic strategy: University of Manchester scientists have used graphene to target and neutralise cancer stem cells while not harming other cells February 26th, 2015

Announcements

Graphene Shows Promise In Eradication Of Stem Cancer Cells March 1st, 2015

Novel Method to Determine Optical Purity of Drug Components March 1st, 2015

Scientific breakthrough in rechargeable batteries: Researchers from Singapore and Québec Team Up to Develop Next-Generation Materials to Power Electronic Devices and Electric Vehicles February 28th, 2015

First detailed microscopy evidence of bacteria at the lower size limit of life: Berkeley Lab research provides comprehensive description of ultra-small bacteria February 28th, 2015

Nanobiotechnology

Untangling DNA with a droplet of water, a pipet and a polymer: With the 'rolling droplet technique,' a DNA-injected water droplet rolls like a ball over a platelet, sticking the DNA to the plate surface February 27th, 2015

Bacteria network for food: Bacteria connect to each other and exchange nutrients February 23rd, 2015

Building tailor-made DNA nanotubes step by step: New, block-by-block assembly method could pave way for applications in opto-electronics, drug delivery February 23rd, 2015

Better batteries inspired by lowly snail shells: Biological molecules can latch onto nanoscale components and lock them into position to make high performing Li-ion battery electrodes, according to new research presented at the 59th annual meeting of the Biophysical Society February 12th, 2015

NanoNews-Digest
The latest news from around the world, FREE




  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More










ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project







© Copyright 1999-2015 7th Wave, Inc. All Rights Reserved PRIVACY POLICY :: CONTACT US :: STATS :: SITE MAP :: ADVERTISE